Source: Annual Congress 2006 - Pathophysiology and treatment of infections in COPD
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Sumitani, Y. Tochino, T. Kamimori, H. Fujiwara, T. Fujikawa (Osaka City, Japan). Effectiveness of 23-valent pneumococcal polysaccharide vaccine in preventing lower respiratory tract infections complicating chronic respiratory failure. Eur Respir J 2006; 28: Suppl. 50, 3384

Member's Comments

No comment yet.

Related content which might interest you: Impaired response to 13-valent pneumococcal conjugate vaccine (PCV13) in children with recurrent respiratory infections and chronic cough. Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function Year: 2021 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Eur Respir Rev 2008; 17: 43-45 Year: 2008 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes Source: Eur Respir J 2014; 43: 545-553 Year: 2013 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Should pneumococcal vaccines be used to prevent LRTI? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Investigation of factors associated with result of pneumococcal urinary antigen in the microbiological investigation of pneumococcal lower respiratory infections Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Simultaneous use of probiotics and vaccines for prevention of pneumonia and respiratory infections in servicemen Source: Eur Respir J 2006; 28: Suppl. 50, 154s Year: 2006 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Effectiveness of polysaccharide pneumococcal vaccination among subjects with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 442s Year: 2006 Results of vaccination against pneumococcal infection in patients with chronic heart failure Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Analysis of efficiency of joint or consistent vaccination with pneumococcal and influenzal vaccines in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017